National Disease Research Interchange

-Philadelphia-based National Disease Research Interchange (NDRI) announces the election of Paul M. Lieberman, Ph.D., to its Board. Lieberman is the Hilary Koprowski, M.D., Endowed Professor, leader of the Gene Expression and Regulation Program, and director of the Center for Chemical Biology & Translational Medicine at The Wistar Institute, a biomedical research leader in cancer, immunology, infectious disease, and vaccine development. Elected on November 12 to a three-year term, Lieberman will bring his experience and insight to the nation’s leading source of human organs, cells and tissues for research.

 The National Disease Research Interchange (NDRI) is pleased to announce its recovery network partners for the developmental Genotype-Tissue Expression (dGTEx) project. The dGTEx project is the first comprehensive public resource correlating gene expression and genetic variation in pediatric tissues from all major organ systems in the human body.  NDRI will partner with multiple organ procurement organizations/tissue banks across the United States.

NDRI and collaborators were awarded a research grant of $12.5M over 5 years to collaborate on the developmental Genotype Expression (dGTEx) project

NDRI was recently awarded a research resource grant of $334,446 from the National Institute on Aging (NIA) to support the development of the Ocular Tissue Resource for Alzheimer’s Disease (OTRAD). While significant advances continue to be made with the identification of blood-based biomarkers for Alzheimer’s disease (AD), there is an emergent interest in the use of ocular imaging or other ocular biomarkers as a parallel approach in early detection of the disease.

NDRI issued a public comment on the Centers for Medicare and Medicaid Services proposed rule entitled "Medicare Program: Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2022 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Proposed Changes to Medicaid Provider Enrollment". This rule dramatically discourages the use and acquisition of human tissues for biomedical research- our comment was posted on June 22. You can read the full submission on our website here: https://ndriresource.org/uploads/attachments/ckqgogkpsedvv96u16sf1qfss-ndripubliccomment.pdf

-Philadelphia-based National Disease Research Interchange (NDRI) announces the election of Paul M. Lieberman, Ph.D., to its Board. Lieberman is the Hilary Koprowski, M.D., Endowed Professor, leader of the Gene Expression and Regulation Program, and director of the Center for Chemical Biology & Translational Medicine at The Wistar Institute, a biomedical research leader in cancer, immunology, infectious disease, and vaccine development. Elected on November 12 to a three-year term, Lieberman will bring his experience and insight to the nation’s leading source of human organs, cells and tissues for research.

 The National Disease Research Interchange (NDRI) is pleased to announce its recovery network partners for the developmental Genotype-Tissue Expression (dGTEx) project. The dGTEx project is the first comprehensive public resource correlating gene expression and genetic variation in pediatric tissues from all major organ systems in the human body.  NDRI will partner with multiple organ procurement organizations/tissue banks across the United States.

NDRI and collaborators were awarded a research grant of $12.5M over 5 years to collaborate on the developmental Genotype Expression (dGTEx) project

NDRI was recently awarded a research resource grant of $334,446 from the National Institute on Aging (NIA) to support the development of the Ocular Tissue Resource for Alzheimer’s Disease (OTRAD). While significant advances continue to be made with the identification of blood-based biomarkers for Alzheimer’s disease (AD), there is an emergent interest in the use of ocular imaging or other ocular biomarkers as a parallel approach in early detection of the disease.

NDRI issued a public comment on the Centers for Medicare and Medicaid Services proposed rule entitled "Medicare Program: Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2022 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Proposed Changes to Medicaid Provider Enrollment". This rule dramatically discourages the use and acquisition of human tissues for biomedical research- our comment was posted on June 22. You can read the full submission on our website here: https://ndriresource.org/uploads/attachments/ckqgogkpsedvv96u16sf1qfss-ndripubliccomment.pdf